CDC & FDA Identify Preliminary COVID-19 Vaccine Safety Signal for Persons Aged 65 Years and Older | CDC
New COVID boosters could get approved using a streamlined review process : Shots - Health News : NPR
For the first time, the FDA is planning to base its decision about whether to authorize new boosters on studies involving mice instead of humans.
"For the FDA to rely on mouse data is just bizarre, in my opinion," says John Moore, an immunologist at Weill Cornell Medicine in New York. "Mouse data are not going to be predictive in any way of what you would see in humans."
B.C. man who had rare, extreme reaction to COVID-19 vaccine still waiting for exemption, government support | CBC News
Omicron largely evades immunity from past infection or two vaccine doses | Imperial News | Imperial College London
Vaccine effectiveness against Omicron
The researchers found a significantly increased risk of developing a symptomatic Omicron case compared to Delta for those who were two or more weeks past their second vaccine dose, and two or more weeks past their booster dose (for AstraZeneca and Pfizer vaccines).
Depending on the estimates used for vaccine effectiveness against symptomatic infection from the Delta variant, this translates into vaccine effectiveness estimates against symptomatic Omicron infection of between 0% and 20% after two doses, and between 55% and 80% after a booster dose. Similar estimates were obtained using genotype data, albeit with greater uncertainty.